Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Akoya Biosciences Inc (AKYA)

Akoya Biosciences Inc (AKYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 195,581
  • Shares Outstanding, K 49,141
  • Annual Sales, $ 96,630 K
  • Annual Income, $ -63,320 K
  • 60-Month Beta 1.48
  • Price/Sales 2.04
  • Price/Cash Flow N/A
  • Price/Book 3.77
Trade AKYA with:

Options Overview Details

View History
  • Implied Volatility 215.20% ( -28.02%)
  • Historical Volatility 40.99%
  • IV Percentile 99%
  • IV Rank 88.41%
  • IV High 243.22% on 04/16/24
  • IV Low 1.48% on 01/09/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 20
  • Volume Avg (30-Day) 13
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,155
  • Open Int (30-Day) 1,100

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.30
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.32
  • Prior Year -0.49
  • Growth Rate Est. (year over year) +38.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.83 +2.09%
on 04/17/24
5.16 -24.26%
on 03/21/24
-1.00 (-20.37%)
since 03/15/24
3-Month
3.83 +2.09%
on 04/17/24
6.31 -38.03%
on 03/04/24
-1.06 (-21.33%)
since 01/17/24
52-Week
3.04 +28.62%
on 10/30/23
8.80 -55.57%
on 06/16/23
-3.59 (-47.87%)
since 04/17/23

Most Recent Stories

More News
Why Shares of Akoya Biosciences Jumped on Tuesday

A rash of insider buying buoyed investor confidence in the medical instrument company.

AKYA : 3.91 (-1.76%)
Akoya Biosciences (AKYA) Reports Q1 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -6.52% and 5.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 3.91 (-1.76%)
CELU : 3.31 (-5.43%)
Akoya Biosciences (AKYA) Reports Q4 Loss, Tops Revenue Estimates

Akoya (AKYA) delivered earnings and revenue surprises of -21.95% and 1.79%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

AKYA : 3.91 (-1.76%)
ACET : 2.27 (+3.65%)
Rapt Therapeutics (RAPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Rapt Therapeutics (RAPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RAPT : 8.04 (-1.11%)
AKYA : 3.91 (-1.76%)
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 1.03%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ABUS : 2.78 (-4.79%)
AKYA : 3.91 (-1.76%)
Certara, Inc. (CERT) Tops Q4 Earnings and Revenue Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 14.29% and 4.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CERT : 16.95 (-0.70%)
AKYA : 3.91 (-1.76%)
Prometheus Biosciences, Inc. (RXDX) Reports Q4 Loss, Misses Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of 1.10% and 6.71%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

RXDX : 199.92 (+0.09%)
AKYA : 3.91 (-1.76%)
Will Akoya Biosciences (AKYA) Report Negative Earnings Next Week? What You Should Know

Akoya (AKYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AKYA : 3.91 (-1.76%)
ICPT : 19.00 (+0.21%)
Ligand Pharmaceuticals (LGND) Surpasses Q4 Earnings and Revenue Estimates

Ligand (LGND) delivered earnings and revenue surprises of 10.57% and 24.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LGND : 78.87 (-1.31%)
AKYA : 3.91 (-1.76%)
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications

Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, to develop multiplex-immunohistochemistry diagnostic solutions...

AKYA : 3.91 (-1.76%)
A : 134.55 (-1.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Akoya Biosciences Inc. offers comprehensive single-cell imaging solutions which allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. The company offer distinct solutions, the CODEX(R) and Phenoptics(TM)...

See More

Key Turning Points

3rd Resistance Point 4.35
2nd Resistance Point 4.23
1st Resistance Point 4.07
Last Price 3.91
1st Support Level 3.79
2nd Support Level 3.67
3rd Support Level 3.51

See More

52-Week High 8.80
Fibonacci 61.8% 6.60
Fibonacci 50% 5.92
Fibonacci 38.2% 5.24
Last Price 3.91
52-Week Low 3.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar